EMA/387121/2016

European Medicines Agency decision

P/0196/2016

of 15 July 2016

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for emicizumab (EMEA-001839-PIP01-15) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Contact EMA www.ema.europa.eu/contact

European Medicines Agency decision

P/0196/2016

of 15 July 2016

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for emicizumab (EMEA-001839-PIP01-15) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Roche Registration Limited on 7 August 2015 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 27 May 2016, in accordance with Article 18 of Regulation (EC) No 1901/2006, and Article 21 of said Regulation and of its own motion in accordance with Article 12 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

(4) It is therefore appropriate to adopt a decision granting a waiver.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for emicizumab, solution for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for emicizumab, solution for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for emicizumab, solution for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Roche Registration Limited, 6 Falcon Way, Shire Park, AL7 1TW - Welwyn Garden City, United Kingdom.

Done at London, 15 July 2016

For the European Medicines Agency
Zaïde Frias
Head of Division
Human Medicines Research and Development Support
(Signature on file)

EMA/PDCO/198270/2016 Corr
London, 27 May 2016

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMEA-001839-PIP01-15

Scope of the application

Active substance(s):

Emicizumab

Condition(s):

Treatment of hereditary factor VIII deficiency

Pharmaceutical form(s):

Solution for injection

Route(s) of administration:

Subcutaneous use

Name/corporate name of the PIP applicant:

Roche Registration Limited

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Roche Registration Limited submitted for agreement to the European Medicines Agency on 7 August 2015 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation.

The procedure started on 15 September 2015.

Supplementary information was provided by the applicant on 07 March 2016. The applicant proposed modifications to the paediatric investigation plan.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5510
Send a question via our website www.ema.europa.eu/contact

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 18 of said Regulation;
   - to grant a deferral in accordance with Article 21 of said Regulation;
   - to grant a waiver for one or more subsets of the paediatric population on its own motion in accordance with Article 12 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition

Treatment of hereditary factor VIII deficiency

The waiver applies to:

- the paediatric population from birth to less than 2 years;
- solution for injection, subcutaneous use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies are not feasible.

2. Paediatric investigation plan

2.1. Condition

Treatment of hereditary factor VIII deficiency

2.1.1. Indication(s) targeted by the PIP

Prevention of bleeding episodes in paediatric patients with haemophilia A with inhibitors to Factor VIII

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Solution for injection

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	2	**Study 1** Development of a lower strength of 60 mg emicizumab/vial, solution for injection (150 mg/mL emicizumab), appropriate to the paediatric population. **Study 2** Development of a lower strength and lower concentration of 30 mg emicizumab/vial, solution for injection (30 mg/mL emicizumab), appropriate to the paediatric population.
Non-clinical studies	0	Not applicable.

Clinical studies	4	**Study 3** Randomised, open label study to evaluate the efficacy, safety and pharmacokinetics of prophylactic emicizumab versus no prophylaxis, in haemophilia A patients with factor VIII (FVIII) inhibitors, 12 years of age and above, in addition to standard of care with episodic bypassing agents. Evaluate efficacy, safety and pharmacokinetics of prophylactic emicizumab in a non-randomized group of patients previously treated with prophylactic bypassing agents. **Study 4** Open-label, single-arm study to evaluate the efficacy, safety and pharmacokinetics of prophylactic emicizumab in paediatrics patients from 2 to less than 12 years of age with haemophilia A and factor VIII (FVIII) inhibitors. **Study 5** Open-label, inter-individual, multiple-ascending dose study to investigate the tolerability, safety, pharmacokinetics, and pharmacodynamic (PD) response of emicizumab in Japanese patients with haemophilia A, 12 years of age and above. **Study 6** Open-label extension of Part C of study 5 to evaluate the safety and the inhibitory effect of emicizumab on bleeding during long-term treatment in Japanese patients with haemophilia A.
Extrapolation, modelling and simulation studies	1	**Study 7** Dose finding Population Pharmacokinetic (PopPK) model.
Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By January 2019
Deferral for one or more measures contained in the paediatric investigation plan:	Yes